Rickard Jason 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed Mar 2, 2022
Insider Transaction Report
Form 4
Rickard Jason
SVP, Chief Operating Officer
Transactions
- Sale
Class A Common Stock
2022-02-28$10.77/sh−1,913$20,603→ 354,162 total - Sale
Class A Common Stock
2022-02-28$10.77/sh−3,150$33,926→ 351,012 total - Sale
Class A Common Stock
2022-02-28$10.77/sh−6,022$64,857→ 344,990 total - Sale
Class A Common Stock
2022-02-28$10.77/sh−11,057$119,084→ 333,933 total - Sale
Class A Common Stock
2022-02-28$10.77/sh−6,820$73,451→ 327,113 total
Footnotes (5)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
- [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
- [F4]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
- [F5]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.